Open AccessEfficacy of Nitazoxanide against Clinical Isolates of Mycobacterium tuberculosis
Author(s) -
Kristina Shigyo,
Oksana Ocheretina,
Yves Mary Merveille,
Warren D. Johnson,
Jean W. Pape,
Carl Nathan,
Daniel W. Fitzgerald
Publication year - 2013
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02542-12
Subject(s) - nitazoxanide , mycobacterium tuberculosis , tuberculosis , microbiology and biotechnology , medicine , virology , biology , immunology , pathology
Nitazoxanide (NTZ) has bactericidal activity against the H37Rv laboratory strain of Mycobacterium tuberculosis with a MIC of 16 μg/ml. However, its efficacy against clinical isolates of M. tuberculosis has not been determined. We found that NTZ's MIC against 50 clinical isolates ranged from 12 to 28 μg/ml with a median of 16 μg/ml and was unaffected by resistance to first- or second-line antituberculosis drugs or a diversity of spoligotypes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom